
Opinion|Videos|January 23, 2025
Innovations and Impact: The Future of Patient Support Services in Hematology-Oncology
Panelists discuss how they envision the future of industry-provided and other patient support services in hematology-oncology, highlighting potential improvements and innovations that could be implemented in the near future.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What do you think is the future of industry-provided and other patient support services in hematology-oncology, and what improvements or innovations would you like to see implemented in the near future?
Advertisement
Related to this article

Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.

A value-based care pilot within Kentucky’s Medicaid program reduced total costs for adults with substance use disorder while improving utilization of evidence-based treatments.

A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
Advertisement
Advertisement

